CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (56,858)	$ (21,593)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,449	3,205
Stock-based compensation	31,263	10,436
Amortization of debt discount and issuance costs	15,724
Amortization of premium (accretion of discount) on investments in marketable debt securities	1,970	(2,855)
Non-cash operating lease expense	2,635
Revaluation of warrant liabilities		717
Deferred income tax	(333)
Changes in assets and liabilities:
Accounts receivable	(5,332)	958
Unbilled revenue	(1,316)	(1,356)
Prepaid expenses and other current assets	(4,833)	(10,843)
Other assets	(11,799)	(1,047)
Accounts payable	927	(1,475)
Accrued and other current liabilities	58	6,893
Operating lease liabilities	7,782
Other long-term liabilities	576	10,689
Deferred revenue	2,924	2,944
Net cash used in operating activities	(13,163)	(3,327)
Cash flows from investing activities:
Purchases of corporate and customer fund short-term investments	(1,486,025)	(830,694)
Proceeds from maturities of corporate and customer fund short-term investments	830,933	596,311
Proceeds from sale of corporate and customer fund short-term investments	119,072	25,337
Increase in other receivables included in funds held for customers	(9,072)	(6,601)
Purchases of property and equipment	(17,062)	(5,736)
Capitalization of internal-use software costs	(1,038)	(489)
Net cash used in investing activities	(563,192)	(221,872)
Cash flows from financing activities:
Proceeds from issuance of convertible senior notes, net of discount and issuance costs	1,129,379
Purchase of capped calls	(87,860)
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs		225,544
Increase in customer fund deposits liability	285,590	24,246
Payments on line of credit borrowings	(2,300)
Proceeds from line of credit borrowings		2,300
Proceeds from exercise of stock options	23,034	1,746
Proceeds from issuance of common stock under the employee stock purchase plan	8,864
Payments of offering costs related to the follow-on public offering	(664)
Proceeds from exercise of stock warrants		144
Payments of deferred debt issuance costs		(151)
Net cash provided by financing activities	1,356,043	253,829
Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents	779,688	28,630
Cash, cash equivalents, restricted cash, and restricted cash equivalents, beginning of period	1,592,377	983,168
Cash, cash equivalents, restricted cash, and restricted cash equivalents, end of period	2,372,065	1,011,798
Reconciliation of cash, cash equivalents, restricted cash, and restricted cash equivalents within the condensed consolidated balance sheets to the amounts shown in the condensed consolidated statements of cash flows above:
Cash and cash equivalents	1,223,724	228,585
Restricted cash included in other current assets	$ 35	$ 256
Restricted Cash, Current, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsCurrent	us-gaap:OtherAssetsCurrent
Restricted cash and restricted cash equivalents included in funds held for customers	$ 1,148,306	$ 782,957
Cash, cash equivalents, restricted cash, and restricted cash equivalents, end of period	$ 2,372,065	$ 1,011,798